PMID- 22690482
OWN - NLM
STAT- MEDLINE
DA  - 20120613
DCOM- 20120814
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 67 Spec No
DP  - 2012
TI  - [Targeted therapy in inflammatory disease: cytokines].
PG  - 22-8
AB  - Summarizing 15 years of therapeutic development of a discipline into a few lines 
      is not an easy thing to do. There are many potential targets involved in the
      inflammatory of auto-immune diseases. Due to the development of biotherapies the 
      choice has become larger, and it is now possible to target practically any
      molecule (cytokine, chemokine or surface receptor for example). Cytokines
      represent the first example of therapeutic target that played a major role in the
      revolution of our discipline. The first part of presentation will focus on the
      pro-inflammatory cytokines (TNFalpha, and interleukines 1 and 6). We shall then, 
      detail the development of a new cytokinic target: BLyS (B lymphocyte stimulator) 
      whose role in the autoimmune diseases appeared recently.
FAU - von Frenckell, C
AU  - von Frenckell C
AD  - Service de Rhumatologie, CHU de Liege, Belgique.
FAU - Malaise, M G
AU  - Malaise MG
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Therapies ciblees en rhumatologie: les cytokines.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Cytokines)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Autoimmune Diseases/*drug therapy
MH  - Cytokines/*antagonists & inhibitors
MH  - Humans
MH  - Inflammation/drug therapy
EDAT- 2012/06/14 06:00
MHDA- 2012/08/15 06:00
CRDT- 2012/06/14 06:00
PST - ppublish
SO  - Rev Med Liege. 2012;67 Spec No:22-8.